ALKEM Q4 FY26 Results & Concall Highlights: Key Takeaways

Q4 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 14 Jun 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹65.6K Cr

- Alkem aims to grow 100 to 150 basis points higher than the overall market growth in India branded generics. - Domestic business expected to grow 100-150 basis points higher than the India market, targeting double-digit growth driven by new launches like semaglutide. - U.S.

From Alkem Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 3 Jul 2026.

Price

₹5,367

Market Cap

₹65.6K Cr

P/E Ratio

27.3

How does Alkem Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Alkem Laboratories Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 3Margin: Rank 3

View Pharmaceuticals & Biotechnology leaderboard →

Alkem Laboratories Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹3.6K Cr, net profit ₹251 Cr.

Full financials →

📊 Revenue & Sales Performance

Rank 3

→Alkem aims to grow 100 to 150 basis points higher than the overall market growth in India branded generics.
→Growth is expected to improve further with the launch and scale-up of GLP-1 (semaglutide) in India, contributing significantly to chronic segment growth.
→Chronic segment currently forms about 22% to 23% of the business, with consistent internal improvement by at least 1% annually.
→The trade generic business showed ~4.3% growth in FY '26, with a focus on profitability; growth is expected to improve in the coming year.
→In the U.S., new product launches such as Tolvaptan (expected Sep-Oct 2026) will support growth, though value erosion on base products may impact.
→Overall, the company expects to sustain or improve current growth momentum across segments, with execution and portfolio expansion key drivers.
→International sales grew by 22.5% in FY '26; continued focus on international markets is expected to sustain healthy momentum.

📈 Profitability & Margins

Rank 3

→Domestic business expected to grow 100-150 basis points higher than the India market, targeting double-digit growth driven by new launches like semaglutide.
→U.S. business looking at high single-digit growth, supported by currency benefits and new launches in H2 FY '27.
→Rest of World (ROW) markets expected to deliver higher teens growth.
→EBITDA margin for FY '27 guided around 20-21%, subject to geopolitical and cost volatility.
→R&D spend maintained at 4-5% of revenue annually; increased spend in Q4 due to filing cycles.
→Margin improvement target of 100 basis points annually challenged by current geopolitical uncertainties; at best margins may be maintained in short term.
→U.S. business EBITDA breakeven timeline extended; India is currently delivering early double-digit EBITDA margins.
→Trade generic segment focusing on profitability over top-line growth, expecting better growth in FY '27.
→Dividend policy to maintain absolute payout with adjusted tax rates leading to improved cash flow from FY '27 onward.

See what Alkem Laboratories Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

Yes

- Occlutech acquisition is the biggest recent investment by Alkem in the last 10 years. - No further acquisitions are planned for at least the next 12 months to focus on integrating Occlutech into Alkem MedTech. - Integration of Occlutech into Alkem MedTech business will take about 12 months. - Continued disciplined investments in expanding differentiated pipeline and operational excellence as part of long-term value creation. - Capital allocation prioritizes balancing dividend payouts with funding for R&D in biosimilars and specialty drugs. - Ongoing investments in new product launches, including semaglutide, and strengthening domestic chronic therapy business. These points reflect Alkem’s strategic investment approach focused on integrating recent acquisitions and investing in organic growth and R&D, with no immediate large-scale new capital expenditure beyond these initiatives.

💰 Fundraising & Capital Structure

No information

→Occlutech acquisition is the major recent investment; no significant further acquisitions planned for next 12 months.
→Focus is on integrating Occlutech into Alkem MedTech business, expected to take around 12 months.
→No explicit mention of new fundraising through debt or equity in the call.
→Capital allocation and risk management focus on balancing dividend payouts and funding for R&D.
→Dividend payout maintained at 25-30% of PAT, expected to continue with adjusted tax regimes.
→Forex exposure is hedged about 80%, and inventory management is proactive to mitigate price volatility.
→No clear indication of fresh equity or debt raising plans; emphasis is on operational growth and cost management.

See what Alkem Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

No information

→During the call, there is no explicit mention of a specific current or expected order book or pending orders for Alkem Laboratories.
→Regarding the U.S. engine manufacturing facility, it was stated that it is early days to declare any significant new order inflows post tariffs and insourcing focus.
→The management indicated that large companies take time to ramp up their own capacities, which affects immediate order inflow visibility.
→No specific quantitative data or forecast on order books or pending orders was shared in the provided transcript.

Key Metrics

1 of 5 growth signals positive in the Q4 FY26 call.

Revenue

Rank 3

Margin

Rank 3

Capex

Yes

Fundraise

No information

Order Book

No information

How does Alkem Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Alkem Laboratories Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

What ALKEM's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
SAIPARENT (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Alkem Laboratories Ltd Q1 FY27 results?

What is Alkem Laboratories Ltd share price analysis?

Alkem Laboratories Ltd currently shows a below-average growth signal. The stock trades at a P/E of 27.3 with a market cap of ₹65,593. Investors should review the full earnings analysis for detailed insights.

Is Alkem Laboratories Ltd planning capital expenditure?

- Occlutech acquisition is the biggest recent investment by Alkem in the last 10 years.

Keep Alkem Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

How does Alkem Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Alkem Laboratories Ltd — Quarterly revenue & net profit

📊 Revenue & Sales Performance

🏗️ Capital Expenditure Plans

📋 Order Book & Pipeline

Key Metrics

Continue your research

What ALKEM's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Frequently Asked Questions